drugset
drugset / Trial / NCT03124368

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

NCT03124368 ↗

Phase 2 Completed 6 enrolled Alexion Pharmaceuticals, Inc. Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedSequentialOpen-labelBasic science

Summary

The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN.

Timeline

Start
2017-08-09
Primary completion
2018-12-21
Completion
2019-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicopan Small molecule 100 mg —
Subject Danicopan Small molecule 200 mg —

Indications

C3 glomerulonephritis dense deposit disease immunoglobulin-mediated membranoproliferative glomerulonephritis membranoproliferative glomerulonephritis